CNS Pharmaceuticals (CNSP) Short Interest Ratio & Short Volume

Short interest is the volume of CNS Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 267,900 shares of CNSP short. 9.67% of CNS Pharmaceuticals' shares are currently sold short. Learn More on CNS Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.67% of CNS Pharmaceuticals' floating shares are currently sold short.

CNS Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 267,900 shares, an increase of 229.9% from the previous total of 81,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

CNS Pharmaceuticals currently has issued a total of 1,440,000 shares. Some of CNS Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. CNS Pharmaceuticals currently has a public float of 2,770,000 shares.

9.67% of CNS Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to CNS Pharmaceuticals: Bionomics Limited (1.82%), FSD Pharma Inc. (0.12%), GeoVax Labs, Inc. (5.29%), Alaunos Therapeutics, Inc. (9.66%), Pasithea Therapeutics Corp. (0.55%), Adial Pharmaceuticals, Inc. (3.71%), TFF Pharmaceuticals, Inc. (4.71%), Lixte Biotechnology Holdings, Inc. (0.67%), Hoth Therapeutics, Inc. (1.07%), Biofrontera Inc. (1.10%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.13 billion), Royal Caribbean Cruises Ltd. ($2.77 billion), Moderna, Inc. ($2.76 billion), Coinbase Global, Inc. ($2.36 billion), Rivian Automotive, Inc. ($2.22 billion), Paychex, Inc. ($2.02 billion), Tractor Supply ($1.81 billion), Enphase Energy, Inc. ($1.65 billion), Chesapeake Energy Co. ($1.62 billion), and Lululemon Athletica Inc. ($1.58 billion). View all of the most shorted stocks.

Short selling CNSP is an investing strategy that aims to generate trading profit from CNS Pharmaceuticals as its price is falling. CNSP shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for CNS Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CNSP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CNSP, twice per month. The most recent reporting period available is July, 15 2024.